Immunochemotherapy with interferon-γ and multidrug therapy for multibacillary leprosy

Barral‐Netto, Manoel; Santos, Sara; Santos, Isabel Cristina dos; Sohsten, Roberto Von; Bittencourt, Achilùa L.; Carvalho, Edgar M.; Barral, Aldina; Waters, Michael F.

doi:10.1016/s0001-706x(98)00097-7

Cited by 12 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar skin lesions have also been reported after subcutaneous injection with recombinant IFN α‐2a and 2b in a patient with multiple sclerosis, chronic type B hepatitis, leukemia, and in patients with acquired immunodeficiency syndrome (26–29). Therapeutic usage of interferon‐γ was also reported in a variety of diseases such as: leprosy, cutaneous leishmaniasis, rheumatoid arthritis, and systemic sclerosis (30–35). Interferon‐γ elicited the adverse effects in studies ranging from mild local skin reaction (delayed type II sensitivity or cutaneous granulomatous reaction) to severe systemic effects.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Ulcerations Following Subcutaneous Interferon β Injection to a Patient with Multiple Sclerosis

Inafuku

Khan

Nagata

et al. 2004

The Journal of Dermatology

View full text Add to dashboard Cite

We report a case treated with interferon beta-1b for multiple sclerosis (MS), who developed severe cutaneous ulcers after six months of therapy. Interferon beta-1b had been used in a regimen of 8 million IU administered subcutaneously through oblique direction of the needle, twice a week. The cutaneous ulcers developed at inoculation sites, as a result of penetration of interferon beta into dermis. Other underlying diseases of coagulative or bleeding disorders or secondary infection were excluded. Histological features of non-specific inflammatory reactions including hyperplastic changes of blood vessels without any evidence of vasculitis were the prominent features in this case. Corticosteroid and interferon beta-1b therapy was continued on restricted sites on the extremities with care not to repeat injections at the same sites previously used. The administration of interferon beta into subcutaneous fatty tissues vertically reduced the incidence of dermal penetration of drug and occurrence of ulcerations in this patient. We review other case reports of severe cutaneous reactions associated with interferon beta-1b therapy in MS patients and conclude that local cytokine-mediated, adverse, immune reaction or non-specific cutaneous inflammatory reaction to interferon beta-1b initiated the skin ulceration long after institution of therapy at the injection sites, and the reaction might be related to the depth of injection.

show abstract

Section: Discussionmentioning

confidence: 99%